MARLBOROUGH, Mass., Feb. 26,
2025 /PRNewswire/ -- Boston Scientific Corporation
(the "Company") (NYSE: BSX) today announced that American Medical
Systems Europe B.V. ("AMS Europe"), its wholly owned finance
subsidiary, has completed a public offering of €850,000,000
aggregate principal amount of 3.000% notes due 2031 and
€650,000,000 aggregate principal amount of 3.250% notes due 2034
(collectively, the "Notes"). The Notes are fully and
unconditionally guaranteed by the Company. Application has been
made for the Notes to be admitted to the Official List of the Irish
Stock Exchange plc trading as Euronext Dublin and to trading on the
Global Exchange Market thereof.
The Company intends to use the net proceeds from the offering,
together with cash on hand, to fund the repayment at maturity of
AMS Europe's 0.750% senior notes due March
8, 2025 and to pay accrued and unpaid interest with respect
to such notes, and for general corporate purposes, which may
include, among other things, short term investments, reduction of
short term debt, funding of working capital and potential future
acquisitions.
About Boston Scientific
Boston Scientific transforms lives through innovative medical
technologies that improve the health of patients around the world.
As a global medical technology leader for more than 45 years, we
advance science for life by providing a broad range of
high-performance solutions that address unmet patient needs and
reduce the cost of health care. Our portfolio of devices and
therapies helps physicians diagnose and treat complex
cardiovascular, respiratory, digestive, oncological, neurological
and urological diseases and conditions. Learn more at
www.bostonscientific.com and connect on LinkedIn and X, formerly
Twitter.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking statements may be identified by words like
"anticipate," "expect," "project," "believe," "plan," "estimate,"
"intend" and similar words. These forward-looking statements are
based on our beliefs, assumptions and estimates using information
available to us at the time and are not intended to be guarantees
of future events or performance. These forward-looking statements
include, among other things, statements regarding the intended use
of proceeds. If our underlying assumptions turn out to be
incorrect, or if certain risks or uncertainties materialize, actual
results could vary materially from the expectations and projections
expressed or implied by our forward-looking statements. These
factors, in some cases, have affected and in the future (together
with other factors) could affect our ability to implement our
business strategy and may cause actual results to differ materially
from those contemplated by the forward-looking statements expressed
in this press release. As a result, readers are cautioned not to
place undue reliance on any of our forward-looking statements.
Risks and uncertainties that may cause such differences include,
among other things: economic conditions, including the impact of
foreign currency fluctuations, future U.S. and global political,
competitive, reimbursement and regulatory conditions; geopolitical
events; manufacturing, distribution and supply chain disruptions
and cost increases; disruptions caused by cybersecurity events;
disruptions caused by public health emergencies or extreme weather
or other climate change-related events; labor shortages and
increases in labor costs; variations in outcomes of ongoing and
future clinical trials and market studies; new product
introductions and the market acceptance of those products; market
competition for our products; expected pricing environment;
expected procedural volumes; the closing and integration of
acquisitions; demographic trends; intellectual property rights;
litigation; financial market conditions; the execution and effect
of our restructuring program; the execution and effect of our
business strategy, including our cost-savings and growth
initiatives; our ability to achieve environmental, social and
governance goals; and future business decisions made by us and our
competitors. New risks and uncertainties may arise from time to
time and are difficult to predict. All of these factors are
difficult or impossible to predict accurately and many of them are
beyond our control. For a further list and description of these and
other important risks and uncertainties that may affect our future
operations, see Part I, Item 1A – Risk Factors in our most recent
Annual Report on Form 10-K filed with the Securities and Exchange
Commission, which we may update in Part II, Item 1A – Risk Factors
in Quarterly Reports on Form 10-Q we will file hereafter. We
disclaim any intention or obligation to publicly update or revise
any forward-looking statements to reflect any change in our
expectations or in events, conditions or circumstances on which
those expectations may be based, or that may affect the likelihood
that actual results will differ from those contained in the
forward-looking statements, except as required by law. This
cautionary statement is applicable to all forward-looking
statements contained in this press release.
CONTACTS:
Chanel Hastings
Media Relations
+1 (508) 382-0288
Chanel.Hastings@bsci.com
Jon Monson
Investor Relations
+1 (508) 683-5450
BSXInvestorRelations@bsci.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/boston-scientific-announces-completion-of-1-5-billion-offering-of-senior-notes-302386390.html
SOURCE Boston Scientific Corporation
